PRELIMINARY NOTICE OF MEETING

The shareholders of the company are hereby invited to attend the Combined Ordinary and Extraordinary General Meeting of Shareholders to be held at 8:30 a.m. on June 22, 2018, at the registered office: 177-181 avenue Pierre Brossolette – 92120 Montrouge, France, to deliberate on the following agenda:

Agenda

Ordinary resolutions:

1. Approval of the annual financial statements for the year ended December 31, 2017.
2. Approval of the consolidated financial statements for the year ended December 31, 2017.
3. Allocation of income for the year.
4. Special report by the Statutory Auditors on regulated agreements and commitments and approval of said agreements.
5. Renewal of the term as Director of Ms. Maïlys FERRERE.
6. Renewal of the term as Director of Ms. Claire GIRAUT.
7. Renewal of the term as Director of Mr. Pierre-Henri BENHAMOU.
8. Renewal of the term as Director of Mr. Michael GOLLER.
9. Renewal of the term as Director of Mr. Torbjorn BJERKE.
10. Renewal of the term as Director of Mr. Daniel SOLAND.
11. Ratification of the provisional appointment as Director of Mr. Michel DE ROSEN.
12. Renewal of the term as Director of Mr. Michel DE ROSEN.
13. Approval of the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. Pierre-Henri BENHAMOU as Chairman and Chief Executive Officer.
14. Approval of the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. David SCHILANSKY as Executive Vice President.
15. Approval of the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. Laurent MARTIN as Executive Vice President.
16. Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of all types to the Chairman and Chief Executive Officer.
17. Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of any kind to be attributed to the Executive Vice President / Chief Financial Officer.
18. Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of all types to the Executive Vice President / Responsible Pharmacist.

19. Authorization to be granted to the Board of Directors for the Company to buy back its own shares pursuant to Article L. 225-209 of the French Commercial Code, duration of authorization, purpose, conditions, and maximum amount, suspension during public offering period.

Extraordinary resolutions:

20. Delegation of powers to be granted to the Board of Directors to increase the share capital by incorporation of reserves, profits and/or premiums, duration of the delegation, maximum par value amount of the capital increase, handling of fractions, suspension during public offering period.

21. Delegation of powers to be granted to the Board of Directors to issue ordinary shares, giving, as necessary, access to ordinary shares or to the allocation of debt securities and/or securities giving access to ordinary shares with pre-emptive rights, duration of delegation, maximum par value amount of the capital increase, option to offer non-subscribed shares to the public, suspension during public offering period.

22. Delegation of powers to be granted to the Board of Directors to issue ordinary shares, giving, as necessary, access to ordinary shares and/or to the allocation of debt securities and/or securities giving access to ordinary shares, without pre-emptive rights and/or in consideration of securities granted as part of a public exchange offer, duration of the authorization, maximum par value of the capital increase, issue price, option to limit the total amount of subscriptions or redistribute non-subscribed securities, suspension during public offering period.

23. Delegation of powers to be granted to the Board of Directors to issue ordinary shares, giving, as necessary, access to ordinary shares and/or to the allocation of debt securities and/or securities giving access to ordinary shares, without pre-emptive rights by an offering covered by paragraph II of Article L.411-2 of the French Monetary and Financial Code, duration of the authorization, maximum par value amount of the capital increase, issue price, option to limit the total amount of subscriptions or redistribute non-subscribed securities, suspension during public offering period.

24. Authorization, in the event of issue without pre-emptive rights, to set the issue price according to the terms set by the General Meeting, within a limit of 10% of the capital per year, suspension during public offering period.

25. Delegation of powers to be granted to the Board of Directors to issue ordinary shares, giving, as necessary, access to ordinary shares and/or to the allocation of debt securities and/or securities giving access to ordinary shares, without pre-emptive rights and/or in consideration of securities reserved for categories of persons with certain characteristics, duration of the authorization, maximum par value amount of the capital increase, issue price, option to limit the total amount of subscriptions or redistribute non-subscribed securities, suspension during public offering period.

26. Authorization to increase the total amount of issues in the event of excess demand, suspension during public offering period;

27. Delegation of powers to be granted to the Board of Directors to increase the share capital by means of the issue of ordinary shares and/or securities giving access to capital, up to the limit of 10% of the capital with a view to compensating contributions in kind of equity securities or securities giving access to the capital, duration of the
28. Overall limitation of the maximum amounts of delegations envisaged under the Twenty-First, Twenty-Second, Twenty-Third, Twenty-Fifth and Twenty-Seventh Resolutions of this Meeting.

29. Delegation of powers to be granted to the Board of Directors to issue stock warrants (BSA), subscription and/or acquisition of new and/or existing stock warrants (BSAANE) and/or subscription and/or acquisition of new and/or existing redeemable stock warrants (BSAAR) without pre-emptive rights, reserved for a category of persons, maximum par value of the capital increase, duration of the delegation, exercise price, suspension during public offering period.

30. Authorization given to the Board of Directors to allocate free existing and/or future shares to salaried employees and/or certain corporate officers of the Company or affiliated companies, shareholder waiver of their pre-emptive rights, duration of the authorization, maximum amount, duration of vesting periods, specifically in case of disability and holding periods.

31. Authorization given to the Board of Directors to grant stock subscription and/or purchase options to members of salaried employees and/or certain corporate officers of the Company or affiliated companies, shareholder waiver of their pre-emptive rights, duration of the authorization, maximum amount, exercise price, maximum term of the option.

32. Delegation of powers to be granted to the Board of Directors to increase capital through the issue of shares of commons stock and/or securities giving rights to equity, without preemptive subscription right, in favor of the members of a company savings plan, pursuant to Articles L. 3332-18 et seq. of the Labor Code, duration of the delegation, maximum nominal amount of the capital increase, issue price, possibility of allotting free shares pursuant to Article L. 3332-21 of the Labor Code.

33. Alignment of the By-laws.

34. Introduction of a casting vote in the favor of the Chairman and amendment of Article 11 of the By-laws.

35. Powers to complete formalities.
PROPOSED RESOLUTIONS

Ordinary resolutions:

First Resolution - Approval of the annual financial statements for the year ended December 31, 2017
The General Meeting, having reviewed the reports of the Board of Directors and the Statutory Auditors concerning the financial year ended December 31, 2017, approves the annual financial statements for the financial year ended on that date, as they were presented, which show a loss of €113,151,106.86.

Second Resolution - Approval of the consolidated financial statements for the year ended December 31, 2017
After having viewed the reports by the Board of Directors and the auditors on the consolidated financial statements as at December 31, 2017, the General Meeting approves these financial statements, as they are submitted, recording a loss of €147,692,970.72.

Third Resolution - Allocation of income for the financial year
The General Meeting, on the proposal of the Board of Directors, decides to allocate the whole of the loss for the financial year ended December 31, 2017, totaling €(113,151,106.86), entirely to the loss brought forward, which as a result, changes from €(164,445,173.96) to €(277,596,280.82).

Pursuant to Article 243 bis of the French General Tax Code, the Meeting notes that it was reminded that no distribution of dividends or income occurred in the past three financial years.

Fourth Resolution - Special report by the Statutory Auditors on regulated agreements and commitments and approval of said agreements
In ruling on the special report by the statutory auditors on regulated agreements and commitments, as presented, the General Meeting approves the new agreements envisaged therein.

Fifth Resolution - Renewal of the term as Observer of Ms. Mailys FERRERE
The General Meeting decides to renew the term as Director of Ms. Mailys FERRERE for a period of two years, to expire at the end of the General Meeting to be held in 2020 to approve the financial statements for the previous financial year.

Sixth Resolution - Renewal of the term as Director of Ms. Claire GIRAUT
The General Meeting decides to renew the term as Director of Ms. Claire GIRAUT for a period of two years, to expire at the end of the General Meeting to be held in 2020 to approve the financial statements for the previous financial year.

Seventh Resolution - Renewal of the term as Director of Mr. Pierre-Henri BENHAMOU
The General Meeting decides to renew the term as Director of Mr. Pierre-Henri BENHAMOU for a period of two years, to expire at the end of the General Meeting to be held in 2020 to approve the financial statements for the previous financial year.

Eighth Resolution - Renewal of the term as Director of Mr. Michael GOLLER
The General Meeting decides to renew the term as Director of Mr. Michael GOLLER for a period of two years, to expire at the end of the General Meeting to be held in 2020 to approve the financial statements for the previous financial year.
Ninth Resolution - Renewal of the term as Director of Mr. Torbjorn BJERKE
The General Meeting decides to renew the term as Director of Mr. Torbjorn BJERKE for a period of two years, to expire at the end of the General Meeting to be held in 2020 to approve the financial statements for the previous financial year.

Tenth Resolution - Renewal of the term as Director of Mr. Daniel SOLAND
The General Meeting decides to renew the term as Director of Mr. Daniel SOLAND for a period of two years, to expire at the end of the General Meeting to be held in 2020 to approve the financial statements for the previous financial year.

Eleventh Resolution - Ratification of the provisional appointment as Director of Mr. Michel DE ROSEN
The General Meeting ratifies the appointment, made provisionally by the Board of Directors during its meeting of May 2, 2018 on Mr. Michel DE ROSEN as Director, to replace Mr. George HORNER following his resignation.

Consequently, Michel DE ROSEN will go about his duties for the remaining term of the appointment of his predecessor, namely until the Meeting to be held in 2018 to approve the financial statements for the previous financial year.

Twelfth Resolution - Renewal of the term as Director of Mr. Michel DE ROSEN
The General Meeting decides to renew the term as Director of Mr. Michel DE ROSEN for a period of two years, to expire at the end of the General Meeting to be held in 2020 to approve the financial statements for the previous financial year.

Thirteenth Resolution - Approval of the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. Pierre-Henri BENHAMOU as Chairman and Chief Executive Officer
The General Meeting, in ruling in application of Article L.225-100, paragraph II of the French Commercial Code, approves the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. Pierre-Henri BENHAMOU as Chairman and Chief Executive Officer, as specified in the Board report section 5.

Fourteenth Resolution – Approval of the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. David SCHILANSKY as Executive Vice President
The General Meeting, in ruling in application of Article L.225-100, paragraph II of the French Commercial Code, approves the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. David SCHILANSKY as Executive Vice President, as specified in the Board report section 5.

Fifteenth Resolution – Approval of the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. Laurent MARTIN as Executive Vice President
The General Meeting, in ruling in application of Article L.225-100, paragraph II of the French Commercial Code, approves the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. Laurent MARTIN as Executive Vice President, as specified in the Board report section 5.

Sixteenth Resolution - Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of all types to the Chairman and Chief Executive Officer
The General Meeting, in ruling in application of Article L.225-37-2 of the French Commercial Code, approves the principles and criteria for the determination, distribution and allocation of
the fixed, variable and extraordinary compensation components and benefits of all types to the Chairman and Chief Executive Officer, as specified in the appendix of the Board report.

**Seventeenth Resolution - Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of any kind to be attributed to the Executive Vice President / Chief Financial Officer**

The General Meeting, in ruling in application of Article L.225-37-2 of the French Commercial Code, approves the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of all types to the Executive Vice President / Chief Financial Officer, as specified in the appendix of the Board report.

**Eighteenth Resolution - Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of all types to the Executive Vice President / Responsible Pharmacist**

The General Meeting, in ruling in application of Article L.225-37-2 of the French Commercial Code, approves the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of all types to the Executive Vice President / Responsible Pharmacist, as specified in the appendix of the Board report.

**Nineteenth Resolution - Authorization to be granted to the Board of Directors for the Company to buy back its own shares pursuant to Article L. 225-209 of the French Commercial Code, duration of authorization, purpose, conditions, and maximum amount, suspension during public offering period**

The General Meeting, having reviewed the report of the Board of Directors, empowers it, for a period of eighteen months, pursuant to Articles L. 225-209 et seq. of the French Commercial Code, to buy back, on one or more occasions and at the times of its choosing, Company shares up to the limit of 10% of the number of shares comprising the share capital, adjusted, if necessary, to take into account the potential increase or reduction of capital transactions having taken place during the course of the program.

This authorization cancels the authorization granted to the Board of Directors by the General Meeting of June 15, 2017 in its Twelfth Ordinary Resolution.

The shares may be bought back in order to:

- support the secondary market or liquidity for DBV TECHNOLOGIES shares through a liquidity agreement with an investment service provider, pursuant to the AMAFI Code of Ethics as permitted by legislation, it being specified that under this scope, the number of shares considered to calculate this limit shall be the number of shares purchased, less the number of shares resold;
- hold the purchased shares and ultimately return them for future exchange or as payment for external growth transactions;
- provide coverage to meet obligations arising from stock option plans and/or free share allocation plans (or similar plans) for the Company’s employees and/or corporate officers, as well as all share allocations arising under company employee savings plans (or similar plans), employee profit-sharing plans and/or any other form of share allocation arrangement for the Company’s employees and/or corporate officers;
- hedge the securities giving access to the Company’s shares, pursuant to current regulations;
- where applicable, cancel the shares acquired, subject to the authorization granted by the General Meeting of June 15, 2017 in its Thirteenth Extraordinary Resolution.
These share purchases may be executed by any means, including the acquisition of blocks of shares, at the times deemed appropriate by the Board of Directors; it is specified that the Board may not, without the prior authorization of the Shareholders’ Meeting, use this authority during a public offer period initiated by a third party for the shares of the Company until the end of the offer period.

The Company does not intend to use options or derivatives.

The maximum purchase price is set at €150 per share. In the event of a capital transaction, in particular a stock split or reverse split, or the allocation of free shares to shareholders, the above-mentioned amount shall be adjusted in the same proportions (multiplier coefficient equal to the ratio between the number of shares comprising the capital before the transaction and the number of shares after the transaction).

The maximum transaction amount is fixed at €150,000,000.

The General Meeting hereby authorizes the Board of Directors to carry out these transactions, set the terms and conditions and methods thereof, finalize all agreements and complete all formalities.

**Extraordinary resolutions:**

**Twentieth Resolution - Delegation of powers to be granted to the Board of Directors to enact a capital increase by incorporation of reserves, profits and/or premiums**

The General Meeting, ruling under the quorum and required majority voting conditions for Extraordinary General Meetings, having reviewed the Board of Directors’ report and pursuant to the provisions of Articles L. 225-129-2 and L. 225-130 of the French Commercial Code:

1) Delegates its competence to the Board of Directors to decide to increase the share capital on one or more occasions, in the periods and according to the methods it may determine, by means of the incorporation into capital of reserves, profits, premiums or other amounts admitted for capitalization, by the issue and free share allocation or by raising the face value of existing ordinary shares or combining these two methods.

2) Decides that if the Board of Directors should use this delegation, in accordance with the provisions of Article L. 225-130 of the French Commercial Code, in the event of the increase of share capital in the form of free share allocation, the fractions formed will not be tradeable nor sellable and the corresponding equity securities will be sold; the amounts received from the sale will be allocated to those entitled within the terms established by the regulation.

3) Sets the term of validity of this authorization at twenty-six months from the date of this General Meeting.

4) Decides that the amount of the share capital increase under this resolution shall not exceed 50% of the share capital as at the date of the decision made by the Board of Directors to increase the share capital, without considering the nominal amount of the capital increase necessary to preserve, in compliance with the law and, if applicable, contractual provisions providing for other adjustments, the rights of those entitled or securities giving access to the Company’s capital.

This maximum amount is separate from all maximum amounts set by the other resolutions of this General Meeting.

5) Decides that the Board cannot, unless authorized in advance by the General Meeting, make use of this authorization in a period public offering initiated by a third party targeting the securities of the Company until the end of the offering period.
6) Confers upon the Board of Directors all powers necessary to implement this resolution and, generally, to take all steps and fulfill all formalities required to the successful completion of each share capital increase, record their completion and to amend the Bylaws accordingly.

7) Notes that this delegation, for the part not used, if applicable, supersedes, as from today’s date, any and all relevant prior delegations.

**Twenty-First Resolution - Delegation of powers to be granted to the Board of Directors to issue ordinary shares giving, as necessary, access to ordinary shares or the allocation of debt securities and/or securities giving access to ordinary shares, with pre-emptive rights**

The General Meeting, having reviewed the Board of Directors’ report and the Statutory Auditors’ special report and pursuant to the French Commercial Code, in particular Articles L. 225-129-2, L. 228-92 and L. 225-132 et seq. thereof:

1) Authorizes the Board of Directors to issue, on one or more occasions, in the proportions and at the times of its choosing, on the French and/or international market either in euros or in foreign currencies or in any other accounting unit set with reference to a basket of currencies:
   - ordinary shares;
   - and/or ordinary shares giving access to the allocation of ordinary shares or debt securities;
   - and/or securities giving access to ordinary shares to be issued.

Pursuant to Article L. 228-93 of the French Commercial Code, the securities to be issued may give rights to ordinary shares of any and all companies that directly or indirectly own over half of its capital or of which the Company directly or indirectly owns over half of the capital.

2) Sets the term of validity of this authorization at twenty-six months from the date of this General Meeting.

3) Decides to fix the limits to the amounts of authorized issues if the Board of Directors should use this delegation of competence:

   The total par value of the ordinary shares that may be issued subject to this authorization may not exceed 20% of the capital existing on the date of the resolution passed by the Board of Directors to increase the share capital.

   To this maximum amount will be added, as necessary, the par value of the capital increase necessary to preserve the rights of the holders of rights or securities giving access to the Company’s capital, pursuant to the law, and where applicable, the contractual stipulations providing for other adjustments.

   The above maximum amounts apply to the overall sum of the maximum nominal amount of shares able to be issued as envisaged in the Twenty-Eighth Resolution.

4) If the Board of Directors should use this delegation of competence under the scope of the issues envisaged in point 1) above, it:

   a/ decides that the issue(s) of ordinary shares or securities giving access to the capital shall be preferentially reserved to shareholders, who may subscribe them on an irrevocable basis;

   b/ decides that if irrevocable subscriptions and, if applicable, revocable securities, have not absorbed the entire issue mentioned in 1), the Board of Directors may use the following options:

      - limit the amount of the issue to the amount of subscriptions, if applicable within the limits established by the regulation.

      - freely allocate all or part of the non-subscribed shares.
- freely allocate all or part of the non-subscribed shares.

5) Decides that the Board of Directors shall be granted, within the limits set above, the powers required to set the terms for the issues and determine the issue price, and if applicable, record the execution of the resulting capital increases, amend the Bylaws accordingly, impute, as it sees fit, the costs of the capital increase to the amount of the related premiums and deduct the necessary sums from this amount to bring the statutory reserve to one tenth of the new share capital after each increase and more generally, perform all tasks required in similar matters.

6) Decides that the Board cannot, unless authorized in advance by the General Meeting, make use of this authorization in a period public offering initiated by a third party targeting the securities of the Company until the end of the offering period.

7) Notes that this delegation, for the part not used, if applicable, supersedes any and all relevant prior delegations.

**Twenty-Second Resolution - Delegation of powers to be granted to the Board of Directors to issue ordinary shares giving, as necessary, access to ordinary shares and/or to the allocation of debt securities and/or securities giving access to ordinary shares, without pre-emptive rights, by public offering**

The General Meeting, having reviewed the Board of Directors’ report and the Statutory Auditors’ special report and pursuant to the French Commercial Code, in particular Articles L. 225-129-2, L 225-136 L. 225-148 and L. 228-92 thereof:

1) Authorizes the Board of Directors to issue, on one or more occasions, in the proportions and at the times of its choosing, on the French and/or international market, by public issue, either in euros or in foreign currencies or in any other accounting unit set with reference to a basket of currencies:
   - ordinary shares;
   - and/or ordinary shares giving access to the allocation of ordinary shares or debt securities;
   - and/or securities giving access to ordinary shares to be issued.

These securities may be issued for the purpose of paying for securities contributed to the Company in a public exchange offer, pursuant to the conditions of Article L. 225-148 of the French Commercial Code.

Pursuant to Article L. 228-93 of the French Commercial Code, the securities to be issued may give rights to ordinary shares of any and all companies that directly or indirectly own over half of its capital or of which the Company directly or indirectly owns over half of the capital.

2) Sets the term of validity of this authorization at twenty-six months from the date of this General Meeting.

3) The total par value of the ordinary shares that may be issued subject to this authorization may not exceed 20% of the capital existing on the date of the resolution passed by the Board of Directors to increase the share capital.

To this maximum amount will be added, as necessary, the par value of the capital increase necessary to preserve the rights of the holders of rights or securities giving access to the Company’s capital, pursuant to the law, and where applicable, the contractual stipulations providing for other adjustments.

This maximum amount applies to the overall sum of the maximum nominal amount of shares able to be issued as envisaged in the Twenty-Eighth Resolution.

4) Decides to cancel shareholders’ pre-emptive rights to ordinary shares and securities giving
access to capital and/or to debt securities covered by this resolution, while retaining the Board of Directors’ option to grant preferential rights to shareholders, pursuant to the law.

5) Decides that the sum due or to be due to the Company for each of the ordinary shares issued under this delegation of powers shall be at least equal to the minimum required by the applicable legal and regulatory provisions at the time the Board of Directors exercises the authorization, having taken into account, in the case of issuing autonomous stock warrants, the issue price of the said warrants.

6) Decides, in the case of the issue of securities in consideration of securities contributed to the Company in a public exchange offer, pursuant to the conditions of Article L. 225-148 of the French Commercial Code, and within the limits set out above, to grant the powers required to set the list of securities for exchange, set the issue conditions, the share-for-share basis, and, if applicable, the amount of the equalization payment in cash, and to set the issue terms.

7) Decides that if subscriptions have not absorbed the entire issue mentioned at 1), the Board of Directors may use the following options:

- limit the amount of the issue to the amount of subscriptions, if applicable within the limits established by the regulation.
- freely allocate all or part of the non-subscribed shares.

8) Decides that the Board of Directors shall be granted, within the limits set above, the powers required to set the terms for the issue(s), and if applicable, record the execution of the resulting capital increases, proceed to amend the Bylaws accordingly, levy, as it sees fit, the costs of the capital increase on the amount of related premiums and deduct the necessary sums from this amount to bring the statutory reserve to one-tenth of the new share capital after each increase and, more generally, perform all tasks required in similar matters.

9) Decides that the Board cannot, unless authorized in advance by the General Meeting, make use of this authorization in a period public offering initiated by a third party targeting the securities of the Company until the end of the offering period.

10) Notes that this delegation, for the part not used, if applicable, supersedes, any and all relevant prior delegations.

**Twenty-Third Resolution - Delegation of powers to be granted to the Board of Directors to issue ordinary shares giving, as necessary, access to ordinary shares and/or to the allocation of debt securities and/or securities giving access to ordinary shares, without preemptive rights, by means of an offer in accordance with point II of Article L.411-2 of the French Monetary and Financial Code**

The General Meeting, having reviewed the Board of Directors’ report and the Statutory Auditors' special report and pursuant to the French Commercial Code, in particular Articles L. 225-129-2, L 225-136 and L. 228-92 thereof:

1) Delegates authority to the Board of Directors to issue, on one or more occasions, in the proportions and at the times of its choosing, on the French and/or international market, by an offering covered by paragraph II of Article L.411-2 of the French Monetary and Financial Code, either in euros or in foreign currencies or in any other account unit set with reference to a basket of currencies:

- ordinary shares;
- and/or ordinary shares giving access to the allocation of ordinary shares or debt securities;
- and/or securities giving access to ordinary shares to be issued.

Pursuant to Article L 228-93 of the French Commercial Code, the securities to be issued may give rights to ordinary shares of any and all companies that directly or indirectly own over half of its capital or of which the Company directly or indirectly owns over half of the
capital.

2) Sets the term of validity of this authorization at twenty-six months from the date of this General Meeting.

3) The total par value of the ordinary shares that may be issued subject to this authorization may not exceed 20% of the capital existing on the date of the resolution passed by the Board of Directors to increase the share capital.

To this maximum amount will be added, as necessary, the par value of the capital increase necessary to preserve the rights of the holders of rights or securities giving access to the Company’s capital, pursuant to the law, and where applicable, the contractual stipulations providing for other adjustments.

This maximum amount applies to the overall sum of the maximum nominal amount of shares able to be issued as envisaged in the Twenty-Eighth Resolution.

4) Decides to cancel shareholders’ pre-emptive rights to ordinary shares and to securities giving access to capital and/or to debt securities covered by this resolution.

5) Decides that the sum due or to be due to the Company for each of the ordinary shares issued under this delegation of powers shall be at least equal to the minimum required by the applicable legal and regulatory provisions at the time that the Board of Directors exercises the authorization, having taken into account, in the event of an issue of autonomous stock warrants, the issue price of the said warrants.

6) Decides that if subscriptions have not absorbed the entire issue mentioned at 1), the Board of Directors may use the following options:

   - limit the amount of the issue to the amount of subscriptions, if applicable within the limits established by the regulation.
   - freely allocate all or part of the non-subscribed shares.

7) Decides that the Board of Directors shall be granted, within the limits set above, the powers required to set the terms for the issue(s), and if applicable, record the execution of the resulting capital increases, amend the Bylaws accordingly, impute, as it sees fit, the costs of the capital increase to the amount of the related premiums and deduct the necessary sums from this amount to bring the statutory reserve to one tenth of the new share capital after each increase and more generally, perform all tasks required in similar matters.

8) Decides that the Board cannot, unless authorized in advance by the General Meeting, make use of this authorization in a period public offering initiated by a third party targeting the securities of the Company until the end of the offering period.

9) Notes that this delegation, for the part not used, if applicable, supersedes any and all relevant prior delegations.

Twenty-Fourth Resolution - Determine the terms for setting the subscription price in the event of an issue without pre-emptive rights, up to an annual maximum of 10% of capital

The General Meeting, having reviewed the Board of Directors’ report and the Statutory Auditors’ special report and pursuant to the French Commercial Code, in particular Article L. 225-136-1, paragraph 2 thereof, authorizes the Board of Directors, which decides to issue ordinary shares or securities giving access to capital, pursuant to the Twenty-Second and Twenty-Third Resolutions, to depart from the price-setting conditions set out in the above-mentioned resolutions, up to a maximum of 10% of the share capital per year, and to set the issue price of similar equity securities to be issued as follows:

The issue price of the equity securities to be issued immediately or at a later date may not be lower than either of the following, at the Board of Directors’ discretion:
- either the weighted average trading price of the Company’s share on the trading day prior to the date on which the issue price is set, with a maximum discount of up to 15%;
- or the average of five consecutive share trading prices selected from the last thirty trading days prior to the date on which the issue price is set, with a maximum discount of up to 15%.

**Twenty-Fifth Resolution – Delegation of powers to be granted to the Board of Directors to issue ordinary shares giving, as necessary, access to ordinary shares and/or to the allocation of debt securities and/or securities giving access to ordinary shares, without pre-emptive rights, for the benefit of categories of persons meeting certain characteristics**

The General Meeting, having reviewed the Board of Directors’ report and the Statutory Auditors’ special report and pursuant to the provisions of the French Commercial Code and specifically Articles L. 225-129-2, L. 225-138 and L. 228-92 of the French Commercial Code:

1) Delegates its competence to the Board of Directors to proceed, on one or more occasions, in the proportions and at the time it deems appropriate, both in France and abroad, without pre-emptive rights to the benefit of the categories of persons defined below, with the issue:
   - ordinary shares;
   - and/or ordinary shares giving access to the allocation of ordinary shares or debt securities;
   - and/or securities giving access to ordinary shares to be issued.

Pursuant to Article L. 228-93 of the French Commercial Code, the securities to be issued may give rights to ordinary shares of any and all companies that directly or indirectly own over half of its capital or of which the Company directly or indirectly owns over half of the capital.

2) Sets the term of validity of this authorization at eighteen months from the date of this General Meeting.

3) The maximum total par value of the share capital increases that may be made subject to this authorization may not exceed 20% of the capital existing on the date of the resolution passed by the Board of Directors to increase the share capital.

To this maximum amount will be added, as necessary, the par value of the capital increase necessary to preserve the rights of the holders of rights or securities giving access to the Company’s capital, pursuant to the law, and where applicable, the contractual stipulations providing for other adjustments.

This maximum limit applies to the amount of the share capital increase fixed in the Twenty-Eighth Resolution.

4) Decides, in accordance with the provisions of Article L. 225-138 of the French Commercial Code, that the issue price of ordinary shares that can be issued under the scope of this delegation of competence will be fixed by the Board of directors and must be at least equal to:
   - either the weighted average trading price of the Company’s share on the trading day prior to the date on which the issue price is set, with a maximum discount of up to 15%;
   - or the average of five consecutive share trading prices selected from the last thirty trading days prior to the date on which the issue price is set, with a maximum discount of up to 15%.

5) Decides to eliminate the pre-emptive rights for the subscription by shareholders of ordinary shares and other securities giving access to the capital to be issued in accordance with Article L. 228-91 of the French Commercial Code, to the benefit of the following categories of persons:

   (i) natural persons or legal entities, including companies, trusts, investment funds or other
placement vehicles, of any form, established under French or foreign law, investing habitually in the pharmaceutical, biotechnological or medical technologies sector; and/or  
(ii) companies, institutions or entities of any form, French or foreign, going about a significant portion of their business in these areas; and/or  
(iii) French or foreign investment service providers or any foreign establishment with a similar status, able to guarantee the realization of an issue intended to be placed with the persons specified under point (i) and/or (ii) above and, under this scope, to subscribe the securities issued.

6) Decides that if subscriptions have not absorbed the entire issue mentioned in 1), the Board of Directors may, at its choice, use, in the order that it determines, one and/or the other of the following faculties:
   - limit the amount of the issue to the amount of subscriptions, if applicable within the limits established by the regulation;
   - freely allocate all or part of the non-subscribed shares amongst the categories of persons defined above.

7) Decides that the Board of Directors shall have full competence to implement this delegation, and therefore to:
   a) decree the conditions of the issue(s);
   b) decree the list of beneficiaries within the above categories;
   c) decree the number of shares to be allocated to each of the beneficiaries;
   d) decide the amount to be issued, the issue price and the amount of the premium that can, if applicable, be demanded at issue;
   e) determine the dates and methods of issue, the nature, form and characteristics of the shares to be created that can, notably, take the form of subordinate or other shares, with limited or unlimited term;
   f) determine the method by which the shares and/or securities issued or to be issued can be released;
   g) fix, if applicable, the methods by which to exercise the rights connected with the securities issued or to be issued and, notably the date, even if retroactive, from which the new shares may be enjoyed, as well as all other terms and conditions involved by the issue;
   h) suspend, if applicable, the exercise of rights connected with the securities issued, for up to three months;
   i) at its sole discretion, impute the cost of the capital increase to the amount of the associated premiums and deduct the necessary sums from this amount to bring the statutory reserve to one tenth of the new share capital after each increase;
   j) record each share capital increase and make the according changes to the Bylaws;
   k) make all adjustments required in compliance with legal provisions and fix the methods according to which the preservation, if applicable, will be assured of the rights of those holding securities giving access at term to capital;
   l) generally, pass all agreements, take all measures and fulfill all formalities required for the issue and financial service of the securities issued in accordance with this delegation and exercise all related rights and, more generally, perform all tasks required in similar matters.

8) Decides that the Board cannot, unless authorized in advance by the General Meeting, make use of this authorization in a period public offering initiated by a third party targeting the
securities of the Company until the end of the offering period.

9) It is acknowledged that the Board of Directors will report back at the next General Shareholders’ Meeting, in compliance with the law and the regulations on the use of this delegation granted under this Resolution.

Twenty-Sixth Resolution - Authorization to increase the total amount of issues in the event of excess demand

Having read the report by the Board of Directors, the General Meeting decides that for each of the issues of ordinary shares or securities giving access to capital, decided in application of the Twenty-First to Twenty-Fifth Resolutions, the number of securities to be issued may be increased under the conditions envisaged by Articles L. 225-135-1 and R. 225-118 of the French Commercial Code and up to the limits fixed by the Meeting, if the Board of Directors notes excess demand.

Twenty-Seventh Resolution - Delegation of powers to be granted to the Board of Directors to increase the share capital by means of the issue of ordinary shares and/or securities giving access to capital up to the limit of 10% of the capital with a view to compensating contributions in kind of equity securities or securities giving access to the capital

The General Meeting, having reviewed the Board of Directors’ and the Statutory Auditors’ reports pursuant to Articles L. 225-147 and L. 228-92 of the French Commercial Code:

1) Authorizes the Board of Directors to proceed, on the basis of the auditors’ report, with the issue of ordinary shares or securities giving access to ordinary shares in view of the remuneration of contributions in kind permitted to the Company and comprising equity securities or securities giving access to the capital if the provisions of Article L. 225-148 of the French Commercial Code do not apply.

2) Sets the term of validity of this authorization at twenty-six months from the date of this General Meeting.

3) Decides that the total amount of the ordinary shares that can be issued under this delegation shall not exceed 10% of the share capital as at the date of this Meeting, without considering the nominal amount of the capital increase necessary to preserve, in compliance with the law and, if applicable, contractual provisions providing for other adjustments, the rights of those entitled or securities giving access to the Company’s capital.

4) This maximum amount applies to the overall sum of the maximum nominal amount of shares able to be issued as envisaged in the Twenty-Eighth Resolution.

5) Delegates all powers to the Board of Directors in order to proceed with the approval of the evaluation of contributions, to decide on the increase of the capital resulting, to record the realization, to allocate, if applicable, to the contribution premium, all expenses and rights stemming from the capital increase, to collect on the contribution premium all amounts necessary to take the statutory reserve up to one tenth of the new capital after each increase and to proceed with the according amendment of the Bylaws and do everything necessary in this respect.

6) Decides that the Board cannot, unless authorized in advance by the General Meeting, make use of this authorization in a period public offering initiated by a third party targeting the securities of the Company until the end of the offering period.

7) Notes that this delegation, for the part not used, if applicable, supersedes any and all relevant prior delegations.
Twenty-Eighth Resolution - Overall limitation of the maximum amounts of delegations envisaged under the Twenty-First, Twenty-Second, Twenty-Third, Twenty-Fifth and Twenty-Seventh Resolutions of this Meeting

Having read the report by the Board of Directors, the General Meeting decides to fix as 65% of the share capital on the date of this Meeting, the total par value of the shares to be issued, by virtue of the Twenty-First, Twenty-Second, Twenty-Third, Twenty-Fifth and Twenty-Seventh Resolutions submitted to this Meeting, it being agreed that to this maximum amount will be added, as necessary, the par value of the capital increase necessary to preserve the rights of the holders of rights or securities giving access to the Company’s capital, pursuant to the law, and where applicable, the contractual stipulations providing for other adjustments.

Twenty-Ninth Resolution - Delegation of powers to be granted to the Board of Directors to issue stock warrants (BSA), subscription and/or acquisition of new and/or existing stock warrants (BSAANE) and/or subscription and/or acquisition of new and/or existing redeemable stock warrants (BSAAR) without pre-emptive rights, reserved for categories of persons

The General Meeting, having reviewed the Board of Directors’ report and the Statutory Auditors’ special report and pursuant to the provisions of Articles L. 225-129-2, L. 225-138 and L. 228-91 of the French Commercial Code:

1) Grants the Board of Directors all necessary powers to carry out, on one or more occasions, in the proportions and at the times of its choosing, in France and abroad, the issue of new stock warrants (BSA), subscription and/or acquisition of new and/or existing stock warrants (BSAANE) and/or subscription and/or acquisition of new and/or existing redeemable stock warrants (BSAAR) without pre-emptive rights, reserved for categories of persons as defined below.

2) Sets the term of validity of this authorization at eighteen months from the date of this General Meeting.

3) Decide that the total par value of shares to which the warrants issued pursuant to this authorization give entitlement may not exceed 0.5% of the capital existing on the day of this Meeting. To this maximum amount will be added, as necessary, the par value of the capital increase necessary to preserve the rights of the holders of rights or securities giving access to the Company’s capital, pursuant to the law, and where applicable, the contractual stipulations providing for other adjustments. This maximum amount is separate from all maximum amounts set by the other resolutions of this General Meeting.

4) Decides that the warrant issue price will be determined by the Board of Directors.

5) Decides that the subscription and/or acquisition price of the shares acquired by exercising the warrants shall be at least equal to the average closing price of DBV TECHNOLOGIES shares for the 20 trading days preceding the decision to issue the warrants, if applicable less the warrant issue price.

6) Decides to withdraw the pre-emptive rights of shareholders to the BSAs, BSAANEs and BSAARs to be issued to the benefit of the following categories of persons: corporate representatives, scientific committee members, employees of the Company and persons associated with the Company and the French or foreign companies related to the Company via a service agreement or as a consultant, in accordance with Article L.225-180 of the French Commercial Code.

7) Stipulates that this authorization means that the shareholders waive their pre-emptive rights to shares that may be issued by the exercising of warrants to the holders of BSAs, BSAANEs and/or BSAARs.

8) Decides that the Board cannot, unless authorized in advance by the General Meeting, make use of this authorization in a period public offering initiated by a third party targeting the securities of the Company until the end of the offering period.
9) Decides that if subscriptions have not absorbed the entire BSA, BSAANE and/or BSAAR issue, the Board of Directors may exercise the following options:

- limit the amount of the issue to the amount of subscriptions, if applicable within the limits established by the regulations;
- freely allocate all or part of the non-subscribed BSAs, BSAANEs and/or BSAARs to persons covered by the categories defined above.

10) Decides that the Board of Directors shall be granted all necessary powers, under the terms set by the law and stipulated above, to issue BSAs, BSAANEs and/or BSAARs and in particular to:

- set the specific list of beneficiaries within the categories of persons defined above, the nature and number of warrants to be allocated to each beneficiary, the number of shares to which each warrant shall give entitlement, the issue price of the warrants and the subscription and/or acquisition price of the shares to which the warrants give entitlement under the terms outlined above, the terms and deadlines for the subscription and exercise of the warrants, the associated adjustment mechanisms and more generally, all terms and conditions with respect to the issue;
- prepare an additional report describing the final terms and conditions of the transaction;
- conduct the necessary share acquisitions within the framework of the share buyback program and to allocate them via the allocation plan;
- record the completion of the capital increase resulting from the exercising of the BSAs, BSAANEs and/or BSAARs and to amend the Bylaws accordingly;
- at its sole discretion, impute the cost of the capital increase to the amount of the associated premiums and deduct the necessary sums from this amount to bring the statutory reserve to one tenth of the new share capital after each increase;
- grant the Chairman and Chief Executive Officer the powers required to enact the capital increase, and to delay the capital increase, within the limits and according to the terms and conditions previously set by the Board of Directors;
- and more generally, perform all tasks required in similar matters.

The General Meeting notes that this authorization supersedes any and all relevant prior authorizations.

**Thirtieth Resolution - Authorization given to the Board of Directors to grant free share subscription and/or purchase options to members of staff and/or certain corporate officers**

The General Meeting, having reviewed the Board of Directors’ report and the Statutory Auditors’ special report, authorizes the Board of Directors, on one or more occasions, in accordance with Articles L. 225-197-1 and L. 225-197-2 of the French Commercial Code, to allocate existing or future ordinary shares in the Company free of charge, reserved for:

- salaried employees of the Company or companies that are directly or indirectly related to it as defined by Article L. 225-197-2 of the French Commercial Code;
- and/or corporate officers who meet the conditions set out in Article L. 225-197-1 of the French Commercial Code.

The total number of shares assigned free of charge pursuant to this Authorization shall not exceed 4.5% of the share capital on the date of this Meeting.

The allocation of shares to beneficiaries will be definitive at the end of a one-year vesting period.

Beneficiaries shall retain these shares for two years from when they are definitively allocated.
By way of exception, final allocation will take place before the end of the vesting period in the event of disability of the beneficiary classified under the second and third categories set out in Article L. 341-4 of the French Social Security Code.

The definitive allocation of the free shares will only occur at the later of the following two dates: (i) expiry of the current vesting period as from their initial allocation and (ii) approval of Viaskin Peanut by the American Food and Drug Administration (U.S.A FDA) (performance condition)

All powers are granted to the Board of Directors to:

- determine the identity of the beneficiaries and the number of shares allocated to each of them;
- If applicable:
  - record the existence of sufficient reserves and upon each grant of shares, to transfer to a reserve account the sums required to pay up new shares to be granted;
  - at the appropriate time, decide on capital increases by means of incorporation of reserves, premiums or profits relating to the issue of new free shares granted;
  - conduct the necessary share acquisitions within the framework of the share buyback program and to allocate them via the allocation plan;
  - determine the impact on beneficiaries’ rights of transactions affecting the share capital or likely to affect the value of shares allocated and enacted during the vesting period and as a result, to modify or adjust, if necessary, the number of shares granted to preserve the beneficiaries’ rights;
  - undertake all useful measures to ensure that beneficiaries comply with the obligation to hold their shares;
  - and generally, in connection with the legislation in effect, perform all duties that the implementation of this authorization may require.

This authorization shall imply that shareholders waive their pre-emptive right to subscribe to newly issued shares through the capitalization of reserves, share premium and profits.

This is given for a duration that expires at the General Meeting to be held in 2019 to rule on the financial statements of the previous year.

For the part not used, if applicable, it supersedes, any and all relevant prior authorizations.

**Thirty-First Resolution - Authorization given to the Board of Directors to grant share subscription and/or purchase options to members of staff (and/or certain corporate officers)**

The General Meeting, having reviewed the Board of Directors’ report and the Statutory Auditors’ special report:

1) Authorizes the Board of Directors, under the provisions of Articles L. 225-177 to L. 225-185 of the French Commercial Code, to grant the beneficiaries indicated below, on one or more occasions, options giving access to new shares in the Company to be issued in respect of a capital increase or to the purchase of existing shares in the Company as a result of buybacks carried out under the terms set by law.

2) Sets the term of validity of this authorization at eighteen months from the date of this General Meeting.

3) Decides that the beneficiaries of these options may only be:
- some or all members of staff, or certain categories of staff, of the Company, and where appropriate, those companies or economic interest groups related to it under the conditions of Article L. 225-180 of the French Commercial Code;
- secondly, those corporate officers who meet the conditions set out in Article L. 225-185 of the French Commercial Code.

4) The total number of options that may be granted by the Board of Directors pursuant to this delegation does not give access to the subscription or purchase of more than 5% of the share capital at the date of this Meeting.

5) Decides that the share subscription and/or purchase price by the beneficiaries will be set on the day the options are granted by the Board of Directors in accordance with the regulations in effect and shall not be less than the average price over the twenty trading days preceding the date of the granting decision.

6) Decides that these share subscription and/or purchase options will be definitively allocated:
   - at the end of a one-year vesting period, up to 25%,
   - then, by the end of this period, up to 12.5% at the end of each six months vesting period.

7) Decide that the exercise of these options will be subject to attendance and the following performance condition: approval of Viaskin Peanut by the American Food and Drug Administration (U.S.A. FDA).

8) Decides that no options may be granted:
   - within the ten trading days before and after the date on which the consolidated financial statements are made public;
   - or in the period between the date on which the Company’s corporate bodies are made aware of information that, if made public, could have a significant impact on the trading price of the Company’s securities, and the date ten trading days after said information is made public;
   - less than twenty trading days after the detachment of shares from a coupon giving access to a dividend or capital increase.

9) Notes that this authorization includes, to the beneficiaries of the options giving access to shares, an express waiver by shareholders of their pre-emptive rights to subscribe shares to be issued as and when the options are exercised.

10) Delegates all powers to the Board of Directors to set the other terms and conditions for the granting of options and their exercise, in particular to:
    - determine the conditions under which the options shall be granted and to draft the list or categories of beneficiaries as scheduled above; to determine, where appropriate, the seniority conditions that must be met by these beneficiaries; to determine the conditions under which the price and number of shares must be adjusted, particularly in the presumptions set out under Articles R. 225-137 to R. 225-142 of the French Commercial Code;
    - define the exercise period(s) for the options granted, with the understanding that the term of the options may not exceed a period of ten years from the grant date;
    - provide the option to temporarily suspend the exercise of options for a maximum period of three months in the event that financial transactions are performed involving the exercise of a right attached to shares;
    - if applicable, conduct the necessary share acquisitions within the framework of the share buyback program and to allocate them via the option plan;
proceed with all acts and formalities required to make final those capital increases that may, if necessary, be performed pursuant to the authorization granted by this resolution; amend the Bylaws accordingly and generally to do whatever is necessary;

- at its own discretion and if it sees fit, impute the cost of increases in share capital to the amount of the associated premiums and deduct the necessary sums from this amount to bring the statutory reserve to one tenth of the new share capital after each increase.

11) Notes that this authorization, for the part not used, if applicable, supersedes any and all relevant prior authorizations.

Thirty-Second Resolution - Delegation of powers to be granted to the Board of Directors to increase capital through the issue of shares of commons stock and/or securities giving rights to equity, without preemptive subscription right, in favor of the members of a Company savings plan, pursuant to Articles L. 3332-18 et seq. of the Labor Code, duration of the delegation, maximum nominal amount of the capital increase, issue price, possibility of allotting free shares pursuant to Article L. 3332-21 of the Labor Code


1) Delegates its competence to the Board of Directors, at its own discretion, to enact a capital increase on one or more occasions through the issue of ordinary shares or securities giving access to the equity securities to be issued by the Company, reserved for members of one or more Company employee savings plans established by the Company and/or affiliated French or international companies under the conditions of Article L.225-180 of the French Commercial Code and of Article L.3344-1 of the French Labor Code.

2) Withdraws the pre-emptive rights to subscribe shares that could be issued subject to this authorization to these persons.

3) Sets the validity of this authorization at twenty-six months from the date of this General Meeting.

4) Limits the maximum par value amount of the increase(s) that may be enacted under this delegation at 2% of the share capital arising from the decision of the Board of Directors to make this increase, with the understanding that this amount is separate from any other maximum amounts set by other delegations relating to capital increases. To this amount will be added, as necessary, the par value of the capital increase necessary to preserve the rights of the holders of rights or securities giving access to the Company’s capital, pursuant to the law, and where applicable, the contractual stipulations providing for other adjustments.

5) Decides that the price of shares to be issued subject to 1) of this authorization may not be more than 20%, or 30% when the vesting period stipulated by the scheme pursuant to Articles L. 3332-25 and L. 3332-26 of the French Labor Code is greater than or equal to ten years) below the average share opening price on the 20 trading days prior to the Board of Directors’ decision to enact the capital increase and the resulting share issue, nor higher than this average.

6) Decides, pursuant to Article L.3332-21 of the French Labor Code, that the Board of Directors may allocate to the beneficiaries defined in the first paragraph above, free shares already issued or to be issued, or other securities giving access to the Company’s capital issued or to be issued (i) in respect of the contribution that may be paid pursuant to the regulations governing the company savings plans and/or (ii) where appropriate, as a discount.

7) Notes that this delegation, for the part not used, if applicable, supersedes any and all relevant prior delegations.
The Board of Directors shall have the discretion to implement, or not implement, this authorization, take all measures and conduct all necessary formalities.

Thirty-Third Resolution - Alignment of the Bylaws

The General Meeting, after a reading of the report of the Board of Directors, decides:

- to consequently amend the first paragraph of Article 13 of the Bylaws as follows, with the rest of the Articles remaining unchanged:

“Article 13 - The Chairman of the Board of Directors

The Board of Directors elects a Chairman, who must be a private individual, from among its members, and determines their remuneration, **in accordance with the conditions laid down by the law. The Chairman is appointed for a period that may not exceed the length of their term of office as a Director. They are eligible for re-election. The Board of Directors may dismiss the Chairman at any time. Any provisions to the contrary will be considered void.**"

- To consequently amend the fifth paragraph of Article 15 of the Bylaws as follows, with the rest of the Articles remaining unchanged:

“The Board of Directors determines the compensation paid to the Chief Executive Officer and the Deputy Chief Executive Officers, **in the conditions envisaged by the law.**

Thirty-Fourth Resolution – Introduction of a casting vote in the favor of the Chairman and amendment of Article 11 of the Bylaws

The General Meeting, after a reading of the report of the Board of Directors, decides:

- to establish a casting vote in the favor of the Meeting Chairman if votes are equal during the deliberations of the Board of Directors, in accordance with the provisions of Article L. 225-37 of the French Commercial Code;
- to consequently amend paragraph 4 of Article 11 of the Bylaws as follows, with the rest of the Articles remaining unchanged:

“**Except where the choice of the method for exercising Executive Management is concerned, decisions will be taken based on a majority vote of the Directors present or represented. The Chairman will have a casting vote in case of an equality of votes.**"

Thirty-Fifth Resolution - Powers to complete formalities

The General Meeting grants all powers to the bearer of an original, a copy or an excerpt of these minutes to carry out all mandatory formalities with respect to registration and publication.

Terms and Conditions of Participation

The Shareholders’ Meeting is open to all shareholders, regardless of the number of shares they hold.

The only shareholders who may participate in the Shareholders’ Meeting are those who can demonstrate that they hold a registered account of shares in their name or in the name of the intermediary registered for their account on the second business day preceding the Shareholders’ Meeting, in this case on **June 20, 2018**, at midnight Paris time:
- either in the registered share accounts kept by the company,
- or in the bearer share accounts kept by the authorized intermediate.
For registered shareholders, simply registering in a share account according to the terms set out above allows them to participate in the Shareholders’ Meeting.

For bearer shareholders, the registration of the shares in the bearer share accounts is established by a shareholding certificate issued by the bookkeeper. To participate in the Shareholders’ Meeting, this shareholding certificate must be sent by the bookkeeper to Société Générale - Shareholders’ Meeting Department - 32, rue du Champ de Tir - CS30812 - 44 308 Nantes Cedex 3 in order to obtain an admission card. Alternatively, the certificate may be presented on the day of the Shareholders’ Meeting by shareholders who have not received their admission card.

Shareholders who are unable to personally attend the Shareholders’ Meeting may choose one of the following options:

a) Grant proxy to the person of their choice under the terms set out in Article L. 225-106 of the French Commercial Code;
b) Send a form of proxy to the company without indicating a proxy;
c) Vote by mail.

Registered shareholders who have been registered for at least one month by the date of the notice of meeting will receive by mail the notification brochure along with a single voting form. In any event, by the twenty-first day prior to the Shareholders’ Meeting, the single form for voting by mail or proxy will be posted on the company’s website (www.dbv-technologies.com).

Once the notice of meeting is issued, bearer shareholders may send a written request to Société Générale to send them this form. Any requests received will be granted no later than six days before the Shareholders’ Meeting.

This form must be returned along with the bearer shareholder’s shareholding certificate. The postal vote form must be received by Société Générale’s Shareholders’ Meeting Department by June 18, 2018.

Shareholders who designate a proxy may provide notification of this delegation by e-mailing a signed, scanned copy of the form along with a photocopy of both sides of their ID card and, if applicable, of their shareholding certificate, to investors@dbv-technologies.com, or by faxing these documents to 01.43.26.10.83. A proxy that is granted may also be revoked by the same procedures.

Requests by shareholders to include items or draft resolutions on the agenda must be sent to the registered office by registered letter with acknowledgment of receipt, e-mailed to investors@dbv-technologies.com or faxed to 01.43.26.10.83. These requests must be received no later than the twenty-fifth day preceding the date of the Shareholders’ Meeting. They may not be sent more than twenty days after the date of this notice.

Requests to include items on the agenda must be accompanied by explanations.

Requests to include draft resolutions on the agenda must be accompanied by the text of the draft resolutions, along with, if applicable, a brief explanation of the reasons, and the information stipulated in paragraph 5 of Article R. 225-83 of the French Commercial Code if the draft resolution concerns the nomination of a candidate to the Board of Directors.

A certificate of registration in the shares account must also be attached to these requests to include items or draft resolutions on the agenda in order to prove, on the date of the request, the possession or representation of the required portion of the capital in accordance with the provisions of Article R. 225-71 of the French Commercial Code. A new certificate proving the
registration in the shares account in the same accounts on the second business day preceding the Shareholders’ Meeting, at midnight Paris time, must be sent to the company.

The text of the draft resolutions presented by shareholders and the list of items added to the agenda upon their request will promptly be posted on the company’s website (www.dbv-technologies.com).

The preparatory documents for the Shareholders’ Meeting described in Article R. 225-73-1 of the French Commercial Code will be posted on the company's website (www.dbv-technologies.com) no later than the twenty-first day prior to the Shareholders’ Meeting.

Please note that the complete text of the documents intended to be presented to the Shareholders’ Meeting in accordance with, in particular, Articles L. 225-115 and R. 225-83 of the French Commercial Code will be made available at the registered office.

In accordance with Article R. 225-84 of the French Commercial Code, any shareholder may submit, to the Chairman of the Company’s Board of Directors, questions in writing until the fourth business day preceding the date of the Shareholders’ Meeting, in this case until June 18, 2018. Such written questions must be sent either by registered mail including a receipt confirmation form, addressed to the registered office, or electronically to the following address: investors@dbv-technologies.com or by fax to +33 (0)1.43.26.10.83. They must be accompanied by a certificate of account registration.

The Board of Directors